139 related articles for article (PubMed ID: 22777071)
1. MDS with del(5q) and associated cKIT D816V positive mastocytosis.
Chan N; Tan SY; Opat S; Shortt J
Pathology; 2012 Aug; 44(5):492-3. PubMed ID: 22777071
[No Abstract] [Full Text] [Related]
2. Systemic mastocytosis with associated clonal hematological non-mast-cell lineage disease: analysis of clinicopathologic features and activating c-kit mutations.
Pullarkat VA; Bueso-Ramos C; Lai R; Kroft S; Wilson CS; Pullarkat ST; Bu X; Thein M; Lee M; Brynes RK
Am J Hematol; 2003 May; 73(1):12-7. PubMed ID: 12701114
[TBL] [Abstract][Full Text] [Related]
3. MDS with 5q deletion and rare
Sanders DS; Fennell T; Chisti MM
BMJ Case Rep; 2019 Apr; 12(4):. PubMed ID: 31005862
[TBL] [Abstract][Full Text] [Related]
4. Systemic mastocytosis associated with myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis: Report of three cases.
Mimiola E; Bomben R; De Matteis G; Perbellini O; Guglielmelli P; Bonifacio M; Parisi A; Gattei V; Zamò A; Mannelli F; García Montero AC; Zanotti R
Hematol Oncol; 2019 Dec; 37(5):628-633. PubMed ID: 31523839
[TBL] [Abstract][Full Text] [Related]
5. Detection of the KIT
Craig JW; Hasserjian RP; Kim AS; Aster JC; Pinkus GS; Hornick JL; Steensma DP; Coleman Lindsley R; DeAngelo DJ; Morgan EA
Mod Pathol; 2020 Jun; 33(6):1135-1145. PubMed ID: 31896808
[TBL] [Abstract][Full Text] [Related]
6. 5q-syndrome presenting as essential thrombocythemia: myelodysplastic syndrome or chronic myeloproliferative disorders?
Koike T; Uesugi Y; Toba K; Narita M; Fuse I; Takahashi M; Shibata A
Leukemia; 1995 Mar; 9(3):517-8. PubMed ID: 7885050
[No Abstract] [Full Text] [Related]
7. Incidence of 17p deletions and TP53 mutation in myelodysplastic syndrome and acute myeloid leukemia with 5q deletion.
Sebaa A; Ades L; Baran-Marzack F; Mozziconacci MJ; Penther D; Dobbelstein S; Stamatoullas A; Récher C; Prebet T; Moulessehoul S; Fenaux P; Eclache V
Genes Chromosomes Cancer; 2012 Dec; 51(12):1086-92. PubMed ID: 22933333
[TBL] [Abstract][Full Text] [Related]
8. Chromosome 5q deletion: specific diagnoses and cytogenetic details among 358 consecutive cases from a single institution.
Santana-Davila R; Holtan SG; Dewald GW; Ketterling RP; Knudson RA; Hanson CA; Steensma DP; Tefferi A
Leuk Res; 2008 Mar; 32(3):407-11. PubMed ID: 17707907
[TBL] [Abstract][Full Text] [Related]
9. Circulating KIT D816V mutation-positive non-mast cells in peripheral blood are characteristic of indolent systemic mastocytosis.
Kristensen T; Broesby-Olsen S; Vestergaard H; Bindslev-Jensen C; Møller MB;
Eur J Haematol; 2012 Jul; 89(1):42-6. PubMed ID: 22469616
[TBL] [Abstract][Full Text] [Related]
10. Concurrent activating KIT mutations in systemic mastocytosis.
Lasho T; Finke C; Zblewski D; Hanson CA; Ketterling RP; Butterfield JH; Tefferi A; Pardanani A
Br J Haematol; 2016 Apr; 173(1):153-6. PubMed ID: 26080027
[No Abstract] [Full Text] [Related]
11. KIT D816V mutation-positive cell fractions in lesional skin biopsies from adults with systemic mastocytosis.
Kristensen T; Broesby-Olsen S; Vestergaard H; Bindslev-Jensen C; Møller MB
Dermatology; 2013; 226(3):233-7. PubMed ID: 23774045
[TBL] [Abstract][Full Text] [Related]
12. Cytogenetic features of 5q deletion and 5q- syndrome in myelodysplastic syndrome in Korea; marker chromosomes proved to be chromosome 5 with interstitial deletion by fluorescence in situ hybridization.
Lee HR; Oh B; Hong DS; Zang DY; Yoon HJ; Kim HJ; Kim I; Ahn JS; Cheong JW; Lee KA; Cho KS; Lee MH; Bang SM; Kim TY; Yun YM; Min YH; Lee YK; Lee DS;
Cancer Genet Cytogenet; 2010 Dec; 203(2):193-202. PubMed ID: 21156233
[TBL] [Abstract][Full Text] [Related]
13. Myelodysplastic syndromes associated with interstitial deletion of chromosome 5q: clinicopathologic correlations and new insights from the pre-lenalidomide era.
Holtan SG; Santana-Davila R; Dewald GW; Khetterling RP; Knudson RA; Hoyer JD; Chen D; Hanson CA; Porrata L; Tefferi A; Steensma DP
Am J Hematol; 2008 Sep; 83(9):708-13. PubMed ID: 18634051
[TBL] [Abstract][Full Text] [Related]
14. Interphase FISH does not improve the detection of DEL(5q) and DEL(20q) in myelodysplastic syndromes.
Douet-Guilbert N; Herry A; LE Bris MJ; Guéganic N; Bovo C; Morel F; DE Braekeleer M
Anticancer Res; 2011 Mar; 31(3):1007-10. PubMed ID: 21498729
[TBL] [Abstract][Full Text] [Related]
15. Molecular characterization of deletions of the long arm of chromosome 5 (del(5q)) in 94 MDS/AML patients.
Douet-Guilbert N; De Braekeleer E; Basinko A; Herry A; Gueganic N; Bovo C; Trillet K; Dos Santos A; Le Bris MJ; Morel F; Eveillard JR; Berthou C; De Braekeleer M
Leukemia; 2012 Jul; 26(7):1695-7. PubMed ID: 22290067
[No Abstract] [Full Text] [Related]
16. Fluorescence in situ hybridization testing for -5/5q, -7/7q, +8, and del(20q) in primary myelodysplastic syndrome correlates with conventional cytogenetics in the setting of an adequate study.
Pitchford CW; Hettinga AC; Reichard KK
Am J Clin Pathol; 2010 Feb; 133(2):260-4. PubMed ID: 20093235
[TBL] [Abstract][Full Text] [Related]
17. Serum tryptase correlates with the KIT D816V mutation burden in adults with indolent systemic mastocytosis.
Kristensen T; Broesby-Olsen S; Vestergaard H; Bindslev-Jensen C; Møller MB;
Eur J Haematol; 2013 Aug; 91(2):106-11. PubMed ID: 23621866
[TBL] [Abstract][Full Text] [Related]
18. The prognostic impact of c-KIT mutation in systemic mastocytosis associated with acute myeloid leukaemia patients.
Won D; Chi HS; Shim H; Jang S; Park CJ; Lee JH
Leuk Res; 2013 Aug; 37(8):883-8. PubMed ID: 23683787
[TBL] [Abstract][Full Text] [Related]
19. Myelodysplastic syndromes with del(5q): indications and strategies for cytogenetic testing.
Haferlach C; Bacher U; Tiu R; Maciejewski JP; List A
Cancer Genet Cytogenet; 2008 Dec; 187(2):101-11. PubMed ID: 19027491
[TBL] [Abstract][Full Text] [Related]
20. NRAS, FLT3 and TP53 mutations in patients with myelodysplastic syndrome and a del(5q).
Fidler C; Watkins F; Bowen DT; Littlewood TJ; Wainscoat JS; Boultwood J
Haematologica; 2004 Jul; 89(7):865-6. PubMed ID: 15257941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
